According to the Chinese medical book's, cancer's is to do with the imbalance of "Chi" & the Toxin cell's reproduce itself. My observation is that Cancer is also related to the food, drinks that people consume & the air one breath.
Drug may prevent relapse of breast cancer
By Liz Szabo, USA TODAY
A drug called anastrozole is better at preventing relapses among certain breast-cancer patients than tamoxifen, the current standard treatment, according to new research presented at a medical conference Wednesday.
Armidex has been found to be a more effective treatment for curtailing the spread of breast cancer.
USA TODAY
The study's authors suggest that postmenopausal women whose tumors grow in response to hormones should take anastrozole, also known by the brand name Arimidex, rather than tamoxifen. Women already taking tamoxifen may want to switch, according to the study's researchers, who presented their findings at the San Antonio Breast Cancer Symposium.
Other cancer experts say that it's too soon to eliminate tamoxifen, noting that doctors don't know the long-term effects of anastrozole, which belongs to a class of drugs called aromatase inhibitors.
Tamoxifen, also known by the brand name Nolvadex, works by blocking the action of estrogen, which can feed certain types of breast tumors.
Tamoxifen eventually stops working, however, allowing cancers to grow back.
That's why doctors typically prescribe tamoxifen for five years before switching to aromatase inhibitors, which prevent the body from making estrogen. Relapsed breast cancer is usually fatal.
In this trial, doctors studied nearly 9,400 breast cancer patients for five years, giving some anastrozole and others tamoxifen, according to the study, also published online in the British medical journal, The Lancet. Compared with tamoxifen — which cuts the risk of cancer recurrence by 50% — anastrozole reduced the chance of relapse by 70% to 80%, according to the study.
AstraZeneca, which makes both drugs, paid for the trial. Its patent for tamoxifen has expired, company spokeswoman Mary Lynn Carver says.
Cancer experts say that tamoxifen remains the standard in premenopausal women. Aromatase inhibitors only work in women whose bodies do not produce estrogen. Read More...
USATODAY.com - Drug may prevent relapse of breast cancer
Drug may prevent relapse of breast cancer
By Liz Szabo, USA TODAY
A drug called anastrozole is better at preventing relapses among certain breast-cancer patients than tamoxifen, the current standard treatment, according to new research presented at a medical conference Wednesday.
Armidex has been found to be a more effective treatment for curtailing the spread of breast cancer.
USA TODAY
The study's authors suggest that postmenopausal women whose tumors grow in response to hormones should take anastrozole, also known by the brand name Arimidex, rather than tamoxifen. Women already taking tamoxifen may want to switch, according to the study's researchers, who presented their findings at the San Antonio Breast Cancer Symposium.
Other cancer experts say that it's too soon to eliminate tamoxifen, noting that doctors don't know the long-term effects of anastrozole, which belongs to a class of drugs called aromatase inhibitors.
Tamoxifen, also known by the brand name Nolvadex, works by blocking the action of estrogen, which can feed certain types of breast tumors.
Tamoxifen eventually stops working, however, allowing cancers to grow back.
That's why doctors typically prescribe tamoxifen for five years before switching to aromatase inhibitors, which prevent the body from making estrogen. Relapsed breast cancer is usually fatal.
In this trial, doctors studied nearly 9,400 breast cancer patients for five years, giving some anastrozole and others tamoxifen, according to the study, also published online in the British medical journal, The Lancet. Compared with tamoxifen — which cuts the risk of cancer recurrence by 50% — anastrozole reduced the chance of relapse by 70% to 80%, according to the study.
AstraZeneca, which makes both drugs, paid for the trial. Its patent for tamoxifen has expired, company spokeswoman Mary Lynn Carver says.
Cancer experts say that tamoxifen remains the standard in premenopausal women. Aromatase inhibitors only work in women whose bodies do not produce estrogen. Read More...
USATODAY.com - Drug may prevent relapse of breast cancer
Comments